Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Otolaryngology

Advanced Options: Injections, Surgery, and Implants

At a Glance

When endolymphatic hydrops causes disabling vertigo despite lifestyle changes and oral medicines, treatment may progress from intratympanic steroids to gentamicin, surgery, or implants. The choice depends mainly on vertigo severity, hearing reserve, and willingness to accept irreversible risks.

When lifestyle changes and oral medications are not enough to control your vertigo, your condition is considered refractory. This simply means the standard “first-line” treatments have failed to provide relief. At this stage, you and your medical team will shift focus toward procedures that directly target the inner ear. These options range from “non-destructive” treatments that aim to save your hearing to “ablative” procedures that intentionally disable parts of the balance system to stop the vertigo [1].

Intratympanic Injections: Direct-to-Ear Medication

The most common next step involves injecting medication through the eardrum into the middle ear. This allows the drug to soak into the inner ear through a thin membrane called the round window [2].

  • Intratympanic Steroids (Non-Ablative): Doctors typically use a high-dose steroid like methylprednisolone. These are considered “hearing-preserving” because they do not intentionally damage the delicate hair cells of the ear [3]. While a major trial found substantial reductions in vertigo attacks, outcomes vary by study, and hearing preservation is not strictly guaranteed [2]. Because they are safer for your hearing, they are often the first choice for patients who still have useful hearing [1].
  • Intratympanic Gentamicin (Ablative): Gentamicin is an antibiotic that is intentionally vestibulotoxic, meaning it is used to damage and shut down the balance sensors in the affected ear [4]. While highly effective at reducing vertigo, it carries a dose-dependent risk of permanent hearing loss, persistent imbalance, and bilateral vestibular hypofunction [3][2]. This is usually reserved for people whose vertigo is severe and who are willing to trade some hearing or balance function for stability [5].

Surgical Pressure Relief: Endolymphatic Sac Surgery

If injections fail, surgery may be an option. The most common “hearing-preserving” surgery is endolymphatic sac decompression. In this procedure, a surgeon removes a small piece of bone in an attempt to give the endolymphatic sac more room to expand [6][7].

Some surgeons also perform a shunt (placing a tiny tube) or duct blockage [8][9]. It is crucial to understand that the mechanism and benefit of these operations remain uncertain. Scientific evidence comparing this surgery to a “sham” (placebo) surgery is considered very low-certainty, making it a controversial option [6]. Many international guidelines view this as an option for specific cases [1].

Destructive Procedures: “Disconnecting” the Ear

For the most severe, intractable cases, doctors may recommend “disconnecting” the balance signals from the brain entirely.

  • Labyrinthectomy: The surgeon removes the balance organs of the inner ear. While outcomes are very high for stopping vertigo, it permanently destroys all remaining hearing and vestibular function in that ear, requiring substantial compensation and rehabilitation [10]. It is only used if your hearing is already “non-serviceable” (very poor) [11].
  • Vestibular Nerve Section: The surgeon cuts only the balance portion of the nerve, attempting to leave the hearing portion intact. This is a complex skull-base surgery that can stop vertigo and preserve hearing in some patients, but it carries substantial risks, including cerebrospinal fluid (CSF) leaks, facial nerve injury, headache, and incomplete vertigo control [12].

Restoring Sound: Cochlear Implants (CI)

If hydrops has already caused severe or profound hearing loss, a cochlear implant may be evaluated [13].

  • Hearing Outcomes: A CI provides substantial electrical access to sound and speech understanding, though it does not restore normal hearing. Outcomes vary, but many report significant improvements, and some experience reduced tinnitus [14][15].
  • Combined Procedures: For patients who need both vertigo control and hearing restoration, a doctor can perform a labyrinthectomy and a cochlear implant at the same time, pending individualized audiology assessment [16][17].

Choosing Your Path

Advanced treatment is a trade-off. Your choice depends on your “hearing reserve” and your tolerance for risk. Before any irreversible procedure, it is vital to ensure your other ear is healthy, as roughly 15% to 30% of patients eventually develop symptoms in both ears (depending on cohort definition) [11][18].

Common questions in this guide

What treatment is usually considered first when medicines do not control hydrops-related vertigo?
Intratympanic steroid injections are often considered before destructive treatments because they aim to control vertigo while preserving useful hearing. The number of injections and the benefit vary, and hearing preservation is not guaranteed.
How is gentamicin different from a steroid injection for endolymphatic hydrops?
Intratympanic gentamicin intentionally damages the balance sensors in the affected ear to reduce vertigo. It can cause permanent hearing loss, lasting imbalance, or reduced balance function in both ears, so it is generally reserved for severe cases after the risks and trade-offs are discussed.
How effective is endolymphatic sac surgery?
The way endolymphatic sac decompression, shunts, and duct blockage work—and how much they help—remains uncertain. Evidence comparing these operations with sham surgery is very low-certainty, so they may be considered only for selected patients after discussing alternatives.
When is a labyrinthectomy used for endolymphatic hydrops?
A labyrinthectomy removes the balance organs and permanently destroys remaining hearing and vestibular function in the treated ear. It is generally reserved for severe, intractable vertigo when hearing in that ear is already non-serviceable.
Can a cochlear implant be placed during a labyrinthectomy?
Some patients with severe or profound hearing loss may have a labyrinthectomy and cochlear implant during the same operation. Whether combined or staged procedures are appropriate depends on residual hearing, balance needs, and an individualized audiology and surgical assessment.
What risks are associated with vestibular nerve section?
Vestibular nerve section may preserve hearing in some patients, but it is complex skull-base surgery. Possible risks include a cerebrospinal fluid leak, facial nerve injury, headache, and incomplete control of vertigo.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.If we choose intratympanic steroids, how many injections are in your standard protocol, and how do we decide if a 'booster' is needed?
  2. 2.Since gentamicin is 'ablative,' what specific tests (like VEMP or caloric) will you use to monitor my vestibular function between injections?
  3. 3.How do you weigh the conflicting research on endolymphatic sac surgery when deciding which of your patients are good candidates?
  4. 4.If I undergo a labyrinthectomy, can we perform a cochlear implant at the same time, or is it better to do them in separate stages?
  5. 5.What are the risks to the facial nerve or for a spinal fluid leak with a vestibular nerve section versus other surgical options?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    International consensus (ICON) on treatment of Ménière's disease.

    Nevoux J, Barbara M, Dornhoffer J, et al.

    European annals of otorhinolaryngology, head and neck diseases 2018; (135(1S)):S29-S32 doi:10.1016/j.anorl.2017.12.006.

    PMID: 29338942
  2. 2

    Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: a randomised, double-blind, comparative effectiveness trial.

    Patel M, Agarwal K, Arshad Q, et al.

    Lancet (London, England) 2016; (388(10061)):2753-2762 doi:10.1016/S0140-6736(16)31461-1.

    PMID: 27865535
  3. 3

    Intratympanic steroid versus gentamicin for treatment of refractory Meniere's disease: A meta-analysis.

    Lee SY, Kim YS, Jeong B, et al.

    American journal of otolaryngology 2021; (42(6)):103086 doi:10.1016/j.amjoto.2021.103086.

    PMID: 34098455
  4. 4

    Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière's disease: a network meta-analysis.

    Hao W, Yu H, Li H

    Journal of neurology 2022; (269(1)):72-86 doi:10.1007/s00415-020-10320-9.

    PMID: 33387016
  5. 5

    [Consensus on intratympanic drug delivery for Menière's disease].

    Li S, Ilmari P, Zhang Q, et al.

    Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery 2022; (36(7)):487-491 doi:10.13201/j.issn.2096-7993.2022.07.001.

    PMID: 35822372
  6. 6

    Surgical interventions for Ménière's disease.

    Lee A, Webster KE, George B, et al.

    The Cochrane database of systematic reviews 2023; (2()):CD015249 doi:10.1002/14651858.CD015249.pub2.

    PMID: 36825750
  7. 7

    Endolymphatic Duct and Sac Decompression: A New Life for an Old Technique.

    Salvinelli F, Bonifacio F, Bigliardo C, et al.

    The journal of international advanced otology 2023; (19(6)):511-516 doi:10.5152/iao.2023.221025.

    PMID: 38088325
  8. 8

    A Comparison of Local Endolymphatic Sac Decompression, Endolymphatic Mastoid Shunt, and Wide Endolymphatic Sac Decompression in the Treatment of Intractable Meniere's Disease: A Short-Term Follow-Up Investigation.

    Zheng G, Liu Y, He J, et al.

    Frontiers in neurology 2022; (13()):810352 doi:10.3389/fneur.2022.810352.

    PMID: 35222247
  9. 9

    Endolymphatic duct blockage for Ménière's disease: a double-blind, randomised controlled trial.

    Schenck AA, van de Berg R, Peters TTA, et al.

    The Lancet regional health. Europe 2026; (68()):101765 doi:10.1016/j.lanepe.2026.101765.

    PMID: 42436934
  10. 10

    Triple Semicircular Canal Plugging versus Labyrinthectomy for Meniere Disease: A Retrospective Study.

    Li X, Lyu Y, Li Y, et al.

    The Laryngoscope 2023; (133(11)):3178-3184 doi:10.1002/lary.30690.

    PMID: 37036082
  11. 11

    Transmastoid Labyrinthectomy for Menière's Disease: Experience and Outcomes.

    Bergmark RW, Semco RS, Abdul-Aziz D, Rauch SD

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2020; (41(10)):1413-1418 doi:10.1097/MAO.0000000000002805.

    PMID: 32810022
  12. 12

    Selective Vestibular Neurectomy through the Presigmoid Retrolabyrinthine Approach in the Treatment of Meniere's Disease.

    Salvinelli F, Bonifacio F, Capece M, et al.

    Brain sciences 2024; (14(4)) doi:10.3390/brainsci14040369.

    PMID: 38672019
  13. 13

    Cochlear implantation in Ménière's disease: a systematic review of literature and pooled analysis.

    Berardino FD, Conte G, Turati F, et al.

    International journal of audiology 2020; (59(6)):406-415 doi:10.1080/14992027.2020.1720922.

    PMID: 32027195
  14. 14

    Cochlear Implantation in Meniere's Disease: A Systematic Review and Meta-Analysis.

    Villavisanis DF, Mavrommatis MA, Berson ER, et al.

    The Laryngoscope 2021; (131(8)):1845-1854 doi:10.1002/lary.29393.

    PMID: 33464598
  15. 15

    Cochlear Implantation Hearing Outcome in Ménière's Disease.

    Chien CY, Kulthaveesup A, Herrmann BS, Rauch SD

    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2022; (166(3)):523-529 doi:10.1177/01945998211012298.

    PMID: 34003698
  16. 16

    Simultaneous Labyrinthectomy and Cochlear Implantation in Patients With Refractory Ménière's Disease.

    Macielak RJ, Harrigan ME, Kaul VF, et al.

    The Annals of otology, rhinology, and laryngology 2025; (134(7)):469-475 doi:10.1177/00034894251322623.

    PMID: 40365654
  17. 17

    Hearing and Vestibular Outcomes in Patients Undergoing Labyrinthectomy and Cochlear Implant in End-Stage Menière's Disease.

    Almashhadani M, Giannuzzi AL, Alkhateeb M, et al.

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2025; (46(9)):1077-1085 doi:10.1097/MAO.0000000000004578.

    PMID: 40690236
  18. 18

    Incidence of Developing Contralateral Ménière's Disease in Patients Undergoing Transmastoid Labyrinthectomy for Unilateral Ménière's Disease.

    Pang B, Costeloe A, Jackson NM, Babu S

    Ear, nose, & throat journal 2021; (100(2)):86-89 doi:10.1177/0145561319854744.

    PMID: 31155943

This page explains advanced treatment options for endolymphatic hydrops for educational purposes and is not medical advice. An otologist or neurotologist can help you weigh hearing preservation, vertigo control, and procedure risks.

Get notified when new evidence is published on endolymphatic hydrops.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.